PriceTargets.com logo

TFF Pharmaceuticals - TFFP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $44.00
  • Forecasted Upside: 14,227.58%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.31 As of 12/3/2024 01:02 PM ET
▼ -0.0149 (-4.63%)

This chart shows the closing price for TFFP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New TFF Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TFFP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TFFP

Analyst Price Target is $44.00
▲ +14,227.58% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for TFF Pharmaceuticals in the last 3 months. The average price target is $44.00, with a high forecast of $44.00 and a low forecast of $44.00. The average price target represents a 14,227.58% upside from the last price of $0.31.

This chart shows the closing price for TFFP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in TFF Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/28/2024Roth MkmLower TargetBuy ➝ Buy$56.00 ➝ $44.00
5/25/2023HC WainwrightLower Target$550.00 ➝ $100.00
3/22/2023JonestradingInitiated CoverageBuy$175.00
3/17/2023HC WainwrightReiterated RatingBuy$550.00
5/19/2022HC WainwrightReiterated RatingBuy$550.00
3/29/2022B. RileyLower TargetBuy$600.00 ➝ $450.00
10/18/2021B. RileyReiterated RatingBuy$600.00
10/8/2021Maxim GroupInitiated CoverageBuy$350.00
6/18/2021B. RileyLower TargetBuy$900.00 ➝ $775.00
3/5/2021HC WainwrightBoost TargetBuy$775.00 ➝ $925.00
3/4/2021Roth CapitalBoost TargetBuy$575.00 ➝ $675.00
2/22/2021HC WainwrightReiterated RatingBuy$775.00
2/8/2021HC WainwrightInitiated CoverageBuy$775.00
2/1/2021B. RileyReiterated RatingBuy$900.00
1/15/2021B. RileyReiterated RatingBuy$900.00
12/7/2020B. RileyInitiated CoverageBuy$900.00
11/6/2020Maxim GroupReiterated RatingBuy$450.00
10/15/2020Roth CapitalBoost TargetBuy$450.00 ➝ $575.00
9/16/2020Maxim GroupReiterated RatingBuy$450.00
8/17/2020Maxim GroupBoost TargetPositive ➝ Buy$300.00 ➝ $450.00
8/14/2020Roth CapitalBoost TargetBuy$375.00 ➝ $450.00
7/30/2020Maxim GroupReiterated RatingBuy$300.00
7/8/2020Maxim GroupInitiated CoverageBuy$300.00
3/27/2020Roth CapitalReiterated RatingBuy
2/27/2020Roth CapitalInitiated CoverageBuy$375.00
(Data available from 12/3/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
TFF Pharmaceuticals logo
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.
Read More

Today's Range

Now: $0.31
Low: $0.30
High: $0.33

50 Day Range

MA: $1.65
Low: $0.30
High: $2.51

52 Week Range

Now: $0.31
Low: $0.27
High: $11.00

Volume

286,927 shs

Average Volume

346,062 shs

Market Capitalization

$1.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.07

Frequently Asked Questions

What sell-side analysts currently cover shares of TFF Pharmaceuticals?

The following Wall Street analysts have issued reports on TFF Pharmaceuticals in the last twelve months: Roth Mkm.
View the latest analyst ratings for TFFP.

What is the current price target for TFF Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for TFF Pharmaceuticals in the last year. Their average twelve-month price target is $44.00, suggesting a possible upside of 13,564.6%. Roth Mkm has the highest price target set, predicting TFFP will reach $44.00 in the next twelve months. Roth Mkm has the lowest price target set, forecasting a price of $44.00 for TFF Pharmaceuticals in the next year.
View the latest price targets for TFFP.

What is the current consensus analyst rating for TFF Pharmaceuticals?

TFF Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TFFP will outperform the market and that investors should add to their positions of TFF Pharmaceuticals.
View the latest ratings for TFFP.

What other companies compete with TFF Pharmaceuticals?

Other companies that are similar to TFF Pharmaceuticals include GRI Bio, Hoth Therapeutics, Aeterna Zentaris, Orgenesis and Bionomics. Learn More about companies similar to TFF Pharmaceuticals.

How do I contact TFF Pharmaceuticals' investor relations team?

TFF Pharmaceuticals' physical mailing address is 2600 Via Fortuna Suite 360, Austin TX, 78746. The company's listed phone number is 817-438-6168 and its investor relations email address is [email protected]. The official website for TFF Pharmaceuticals is www.tffpharma.com. Learn More about contacing TFF Pharmaceuticals investor relations.